Compare CREG & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREG | ITRM |
|---|---|---|
| Founded | N/A | 2015 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | CREG | ITRM |
|---|---|---|
| Price | $1.20 | $0.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 87.0K | ★ 918.4K |
| Earning Date | 02-14-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $173,659.00 | ★ $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $193.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $0.26 |
| 52 Week High | $14.70 | $1.75 |
| Indicator | CREG | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 45.27 |
| Support Level | $1.16 | $0.31 |
| Resistance Level | $1.34 | $0.39 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 19.34 | 32.08 |
Smart Powerr Corp is a pioneer in waste energy recycling and a developer of energy efficiency solutions for various energy-intensive industries in China. It uses the Build-Operate-Transfer (BOT) model to provide energy-saving and recovery facilities for multiple energy-intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. The company offers waste energy recycling systems to companies for use in nonferrous metal plants. It constructs its projects at its customer's facility and the electricity produced is used on-site by the customer.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.